Maintenance chemotherapy has a long history of use in hematologic malignancies, in which
the benefits are considerable in terms of survival and quality of life. Recently, several studies …

During the past 10 years, the treatment of advanced-stage non-small cell lung cancer
(NSCLC) has become increasingly complex, and debate continues regarding the optimal …

Background: Maintenance strategy has been used to improve survival in non-small cell lung
cancer (NSCLC). We investigated whether switch maintenance therapy with vinorelbine …

Non-small cell lung cancer (NSCLC) remains the most common cause of cancer-related
death in the United States. Survival for patients with advanced disease remains meager with …

Background Most patients with metastatic non-small cell lung cancer (NSCLC) will face
treatment with systemic therapy. Current clinical studies are demonstrating improvements in …

Background In advanced non-small-cell lung cancer (NSCLC), with the increasing number
of active compounds available in salvage settings, survival after progression to first-line …

Two phase III trials have shown that prolonging chemotherapy duration improves outcome in
patients with nonsquamous non-small-cell lung cancer. Pemetrexed versus placebo, and …

Abstract Background Maintenance treatment (MTx) in responders following first-line
treatment has been investigated and practiced for many cancers. Modeling and simulation …

Objectives In advanced non-small cell lung cancer (NSCLC), maintenance therapy has
emerged as a novel therapeutic reference for patients with non-progressive disease after …

7143 Background: There is no defined role for MT beyond 4 cycles of combination
chemotherapy for advanced NSCLC. Our previously reported randomized, Phase III trial …